{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:34:44Z","timestamp":1787243684785,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,15]]},"DOI":"10.1093\/cid\/cix158","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T15:07:23Z","timestamp":1487171243000},"page":"1350-1359","source":"Crossref","is-referenced-by-count":47,"title":["Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis"],"prefix":"10.1093","volume":"64","author":[{"given":"Neesha","family":"Rockwood","sequence":"first","affiliation":[{"name":"Department of Medicine, Imperial College London, United Kingdom;"},{"name":"Wellcome Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotam G.","family":"Pasipanodya","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Sirgel","sequence":"additional","affiliation":[{"name":"Department of Science and Technology\/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research\/ South African Medical Research Foundation Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Health Sciences, Stellenbosch University, Tygerberg,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Lesosky","sequence":"additional","affiliation":[{"name":"Wellcome Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa;"},{"name":"Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas;"},{"name":"Department of Medicine, University of Cape Town, South Africa; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College London, United Kingdom;"},{"name":"Department of Medicine, University of Cape Town, South Africa; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College London, United Kingdom;"},{"name":"Wellcome Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa;"},{"name":"Department of Medicine, University of Cape Town, South Africa; and"},{"name":"Francis Crick Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"key\n\t\t\t\t20180328150052_CIT0001","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2015"},{"key":"key\n\t\t\t\t20180328150052_CIT0002","first-page":"423","article-title":"Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis","volume":"133","author":"Mitchison","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0003","doi-asserted-by":"crossref","first-page":"e63840","DOI":"10.1371\/journal.pone.0063840","article-title":"An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse","volume":"8","author":"Phillips","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328150052_CIT0004","doi-asserted-by":"crossref","first-page":"e71116","DOI":"10.1371\/journal.pone.0071116","article-title":"Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model","volume":"8","author":"Wallis","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328150052_CIT0005","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1164\/rccm.2302003","article-title":"The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment","volume":"167","author":"Burman","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180328150052_CIT0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1473-3099(14)70885-0","article-title":"Shortening treatment of tuberculosis: lessons from fluoroquinolone trials","volume":"15","author":"Nimmo","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0007","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0008","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0009","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0010","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0011","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.05208-11","article-title":"Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions","volume":"56","author":"Kjellsson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0012","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01520-08","article-title":"Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs","volume":"53","author":"Goutelle","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0013","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"Srivastava","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0014","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/jac\/dkf214","article-title":"Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy","volume":"50","author":"Ziglam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0015","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20180328150052_CIT0016","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/cid\/civ427","article-title":"Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00749-10","article-title":"An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future","volume":"55","author":"Pasipanodya","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0018","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.03931-14","article-title":"Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis","volume":"59","author":"Chigutsa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0020","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1128\/AAC.02468-12","article-title":"Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients","volume":"57","author":"Burhan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0021","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10096-007-0454-6","article-title":"Peak plasma rifampicin level in tuberculosis patients with slow culture conversion","volume":"27","author":"Chang","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0022","article-title":"Serum levels of anti-tuberculosis drugs and their effect on tuberculosis treatment outcome","author":"Park","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0023","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1378\/chest.113.5.1178","article-title":"Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients","volume":"113","author":"Kimerling","year":"1998","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180328150052_CIT0024","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3201\/eid1610.100374","article-title":"Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA","volume":"16","author":"Heysell","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180328150052_CIT0026","volume-title":"Treatment of tuberculosis guidelines","author":"World Health Organization","year":"2010","edition":"4"},{"key":"key\n\t\t\t\t20180328150052_CIT0027","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1128\/AAC.00480-16","article-title":"HIV-1 coinfection does not reduce exposure to rifampin, isoniazid, and pyrazinamide in South African tuberculosis outpatients","volume":"60","author":"Rockwood","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0028","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0009-9120(95)02024-1","article-title":"In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein","volume":"29","author":"Woo","year":"1996","journal-title":"Clin Biochem"},{"issue":"database issue","key":"key\n\t\t\t\t20180328150052_CIT0029","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"key\n\t\t\t\t20180328150052_CIT0030","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/civ195","article-title":"Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis","volume":"61","author":"Sloan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/096228029500400303","article-title":"An introduction to multivariate adaptive regression splines","volume":"4","author":"Friedman","year":"1995","journal-title":"Stat Methods Med Res"},{"key":"key\n\t\t\t\t20180328150052_CIT0033","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"key\n\t\t\t\t20180328150052_CIT0034","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0035","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/AAC.00830-09","article-title":"Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis","volume":"53","author":"Almeida","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0036","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1203636109","article-title":"Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide","volume":"109","author":"Grosset","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180328150052_CIT0037","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1128\/AAC.00269-11","article-title":"Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling","volume":"55","author":"Srivastava","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328150052_CIT0038","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1164\/ajrccm\/138.4.999","article-title":"Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan","volume":"138","author":"Suo","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180328150052_CIT0039","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/jac\/dkp262","article-title":"Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis","volume":"64","author":"Sch\u00f6n","year":"2009","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/64\/10\/1350\/17827810\/cix158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T17:16:55Z","timestamp":1522257415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/64\/10\/1350\/2999729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,2,16]]},"published-print":{"date-parts":[[2017,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix158","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,15]]},"published":{"date-parts":[[2017,2,16]]}}}